OXFORD BIODYNAMICS LS-,01 Aktie Logo
GB00BD5H8572
A2DH0R
LMQ.F

OXFORD BIODYNAMICS LS-,01 Aktie

Caricamento quotazioni...

Previsioni

Non sono disponibili dati degli analisti per questa azienda.


  • Oxford BioDynamics brings prostate cancer test EpiSwitch PSE to the UAE

    Oxford BioDynamics has entered into a partnership with the Dubai London Clinics & Hospitals Group (DLCH) to offer the prostate cancer test EpiSwitch PSE across DLCH’s clinic and hospital network in the United Arab Emirates. Patient blood samples will be collected at DLCH facilities and analyzed at Oxford BioDynamics’ laboratory in the UK; the clinical workflow has been validated by both partners. The agreement is the first commercial rollout of the test in the Gulf region; market launch, local market development and collaboration with payers are intended to gradually increase test volumes. » Altro su de.investing.com


  • Oxford BioDynamics secures £9.15m through conditional share issue

    Oxford BioDynamics raised about £9.15m by placing 9.15 billion new ordinary shares at £0.001 each; after fees roughly £8.4m is expected. The proceeds are intended to fund platform partnerships for EpiSwitch‑Orion, expansion of the prostate cancer test, development of a test for response to checkpoint inhibitors and completion of a colorectal cancer study. Without the financing, cash is expected to be exhausted in early September 2026; the transaction requires shareholder approval (AGM 26 Aug.) and AIM approval (27 Aug.). The company reported a significant capital loss under the Companies Act, and the board is considering alternative financing options, a sale or an orderly wind‑down if the proposal is rejected. » Altro su de.investing.com


  • Oxford BioDynamics partners with MK Commercial Group to expand US sales

    Oxford BioDynamics has signed a sales agreement with MK Commercial Group to strengthen US distribution of EpiSwitch PSE. Initially seven field sales advisors will be deployed, with the number able to rise to as many as 35 to cover key population centers such as New Jersey, Washington D.C., Virginia, Georgia and Chicago. According to the company, the test for triage after elevated PSA levels has a positive predictive value of 93% and a specificity of 97% and is intended to reduce unnecessary biopsies. The sales representatives will operate under the commercial management of Oxford BioDynamics and will complement the existing sales infrastructure in Frederick, Maryland. » Altro su de.investing.com

Nel 2022, OXFORD BIODYNAMICS LS-,01 Aktie ha già distribuito 0,0195 € di dividendi. L'ultimo pagamento è avvenuto a gennaio 2022.

Dati finanziari dell'azienda

Nell'ultimo trimestre, OXFORD BIODYNAMICS LS-,01 Aktie ha registrato ricavi pari a 785,98K € e un utile netto di -5,11 Mln €
(EUR) marzo 2026
YoY
Ricavi 785,98K -
Utile lordo -276,87K -
Utile netto -5,11 Mln -
EBITDA -4,73 Mln -

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
3,22 Mln €
Numero di azioni
2,13 Mld
Massimo/minimo a 52 settimane
0,00873 € - 0,000931 €
Dividendi No
Beta
-0,15
Rapporto P/E
-0,33
Rapporto PEG
0,00
Rapporto P/B
1,52
Rapporto P/S
2,32

Profilo aziendale

Oxford BioDynamics Plc, ein Biotechnologieunternehmen, erforscht und entwickelt Biomarker für den Einsatz in der pharmazeutischen und biotechnologischen Industrie, hauptsächlich in den Vereinigten Staaten und international. Das Unternehmen bietet EpiSwitch an, eine firmeneigene Technologieplattform für die Entdeckung, Bewertung, Validierung und Überwachung von epigenetischen Biomarkern, die als Chromosomenkonformationssignaturen bekannt sind und für medizinische Testkits, Krankheitsvorhersage, Diagnose und Behandlung verwendet werden. Zu den Produkten des Unternehmens gehören EpiSwitch CiRT (Checkpoint Inhibitor Response Test), ein validierter Prognosetest zur Vorhersage des Ansprechens auf eine Checkpoint-Inhibitor-Immuntherapie; EpiSwitch CST (Covid Severity Test), ein fortschrittlicher Bluttest zur Vorhersage des Schweregrads von COVID-19 bei Erwachsenen; und EpiSwitch Explorer Array Kit für hochauflösende 3D-Genomprofilierung und Biomarker-Entdeckung. Oxford BioDynamics Plc wurde im Jahr 2007 gegründet und hat seinen Hauptsitz in Oxford, Vereinigtes Königreich.

Nome
OXFORD BIODYNAMICS LS-,01 Aktie
CEO
Richard Compton
Sede centrale Oxford, ox
Regno Unito
Sito web
Quotazione in borsa
06/12/2016
Dipendenti 37

Simboli di borsa

Borsa Simbolo
Frankfurt
LMQ.F
London
OBD.L
🍪

Parqet  usa i cookie. Scopri di più